{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:03:27Z","timestamp":1762376607325,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare, Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.08.031","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T16:00:41Z","timestamp":1567872041000},"page":"6573-6579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Regulatory aspects of quality and safety for live recombinant viral vaccines against infectious diseases in Japan"],"prefix":"10.1016","volume":"37","author":[{"given":"Akira","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsunari","family":"Kihira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ippei","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyuki","family":"Itamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunobu","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzaburo","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhide","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.08.031_b0005","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1016\/j.vaccine.2016.06.059","article-title":"Vector-based genetically modified vaccines: exploiting Jenner's legacy","volume":"34","author":"Ramezanpour","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.031_b0010","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2019.08.031_b0015","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.031_b0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.031_b0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vaccine.2014.09.035","article-title":"The brighton collaboration viral vector vaccines safety working group (V3SWG)","volume":"33","author":"Chen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.031_b0030","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains","volume":"34","author":"Condit","year":"2016","journal-title":"Vaccine"},{"issue":"38","key":"10.1016\/j.vaccine.2019.08.031_b0035","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1016\/j.vaccine.2018.08.085","article-title":"Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines","volume":"37","author":"Kochhar","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.031_b0040","unstructured":"CHMP. Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. EMA\/CHMP\/VWP\/141697\/2009; 2010."},{"key":"10.1016\/j.vaccine.2019.08.031_b0045","unstructured":"RVVRG. Concept paper (in Japanese). https:\/\/www.pmda.go.jp\/files\/000226581.pdf."},{"key":"10.1016\/j.vaccine.2019.08.031_b0050","unstructured":"MHLW. Guideline for nonclinical studies of preventive vaccines for infectious diseases. Notification No. 0527-1 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW; 2010."},{"key":"10.1016\/j.vaccine.2019.08.031_b0055","unstructured":"MHLW. Guideline for clinical studies of preventive vaccines for infectious diseases. Notification No. 0527-5 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW; 2010."},{"key":"10.1016\/j.vaccine.2019.08.031_b0060","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2019.08.031_b0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","article-title":"Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"33","author":"Monath","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.031_b0070","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1586\/erv.10.139","article-title":"IMOJEV((R)): a Yellow fever virus-based novel Japanese encephalitis vaccine","volume":"9","author":"Appaiahgari","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.08.031_b0075","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2019.08.031_b0080","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.031_b0085","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S1473-3099(17)30541-8","article-title":"Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report","volume":"17","author":"Gsell","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.031_b0090","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2019.08.031_b0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified vaccinia virus ankara: history, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2019.08.031_b0100","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1016\/j.vaccine.2009.05.018","article-title":"Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity","volume":"27","author":"Gudmundsdotter","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.031_b0105","unstructured":"ICH. General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors; 2006."},{"key":"10.1016\/j.vaccine.2019.08.031_b0110","unstructured":"ICH. General Principles to Address Virus and Vector Shedding; 2009."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.08.031_b0115","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.031_b0120","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1086\/374244","article-title":"Progressive vaccinia","volume":"36","author":"Bray","year":"2003","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2019.08.031_b0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2004.05.004","article-title":"Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination","volume":"44","author":"Eckart","year":"2004","journal-title":"J Am Coll Cardiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:36:11Z","timestamp":1759401371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19310953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":25,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X19310953"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory aspects of quality and safety for live recombinant viral vaccines against infectious diseases in Japan","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}